SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ: LGND).  Under the terms of the acquisition agreement, which is structured like a tender offer, the Company's shareholders will receive $12.00 in cash for each share of PFNX common stock that they own.  Additionally, PFNX shareholders will receive a one-time contingent value right of $2.00 ("CVR") in the event a predefined regulatory milestone is achieved by December 31, 2021.

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own PFNX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771

WeissLaw is investigating whether PFNX's board acted to maximize shareholder value in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the valuation of the deal and the proposed CVR will be fully and fairly disclosed to PFNX shareholders. 

Notably, at least one analyst set a target price of $20.00 per PFNX share, or $8.00 above the per-share offer price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at

Cision View original content to download multimedia:


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.